Gordonibacter urolithinfaciens: Pioneering the Future of Urolithin based Microbiome Therapeutics
In the rapidly evolving landscape of Live Biotherapeutic Products (LBPs), the gut-lung-brain axis and microbial metabolites have emerged as the next frontier of precision medicine. At the heart of this revolution lies Gordonibacter urolithinfaciens, a specialized anaerobic bacterium with the unique metabolic capacity to convert dietary ellagitannins into bioactive urolithins.
As a leading Contract Research Organization (CRO) specializing in preclinical research for live biotherapeutics, we provide a comprehensive Gordonibacter urolithinfaciens-based Microbiome Therapeutic Research Service. We bridge the gap between complex microbial ecology and clinical application, offering the high-fidelity data and specialized products necessary to accelerate your drug discovery pipeline. Our mission is to empower biopharmaceutical innovators with the high-resolution data and specialized models needed to transform this unique strain into the next generation of life-changing therapies.
Overview: The Gatekeeper of Urolithin Production
Gordonibacter urolithinfaciens is a gram-positive, obligate anaerobic bacterium belonging to the Eggerthellaceae family. Originally isolated from human feces, it is one of the few identified species capable of metabolizing ellagitannins and ellagic acid—compounds found in pomegranates, berries, and walnuts—into Urolithin A and B.
The Metabolic Bridge
The therapeutic value of G. urolithinfaciens lies in its specific enzymatic machinery. While humans consume polyphenol-rich diets, we lack the internal enzymes to break down complex ellagitannins. G. urolithinfaciens acts as a metabolic "factory," performing the dehydroxylation steps required to produce Urolithins. These metabolites, particularly Urolithin A, are highly bioavailable and exhibit potent anti-inflammatory, anti-oxidative, and anti-aging properties.
Strategic Importance in LBPs
As the industry shifts toward Precision Microbiome Medicine, G. urolithinfaciens stands out because its presence (or absence) determines an individual's "metabotype." Researching this strain allows for the development of:
Pure LBPs: Direct administration of the strain.
Synbiotics: Combining the strain with specific polyphenol precursors.
Postbiotics: Using the metabolites produced by the strain in standardized dosages.
Our Preclinical Research Services
As a specialized CRO, we offer an end-to-end service pipeline for companies looking to develop Gordonibacter-based therapeutics. Our facilities are optimized for the handling of strict anaerobes and the complex analytical chemistry of microbiome metabolites.
Strain Characterization & Optimization
Genomic Profiling: Whole Genome Sequencing (WGS) to identify metabolic pathways, antibiotic resistance genes (ARGs), and virulence factors.
Metabolic Flux Analysis: Quantifying the efficiency of ellagitannin-to-urolithin conversion under various conditions.
Growth Optimization: Developing specialized anaerobic media and fermentation protocols to ensure high-titer yields.
Intestinal Barrier Models: Using Caco-2 cell lines to measure the effect of G. urolithinfaciens on tight junction protein expression (e.g., Zonulin, Occludin).
Immune Modulation Assays: Co-culture systems with PBMC or RAW 264.7 macrophages to evaluate cytokine profiles (IL-10, TNF-α, IL-6).
Mitophagy Flux Assays: High-resolution imaging to track mitochondrial turnover in response to bacterial supernatants.
Gordonibacter urolithinfaciens was isolated from human feces of a healthy volunteer. It is a Gram-positive bacteria belonging to the recent family Eggerthellaceae.
This product contains high-quality, intact genomic DNA isolated from Gordonibacter urolithinfaciens Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Research Applications: Targeting Chronic and Degenerative Diseases
Current research into Gordonibacter urolithinfaciens and its metabolites spans multiple therapeutic areas. Its primary mechanism of action—the induction of mitophagy (the clearing of damaged mitochondria)—makes it a versatile candidate for age-related and inflammatory conditions.
Research indicates that urolithins produced by Gordonibacter can improve insulin sensitivity and modulate lipid metabolism. In preclinical models, the presence of this strain is associated with reduced systemic inflammation, a key driver of Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
By promoting mitophagy, the metabolites of G. urolithinfaciens enhance muscle function and cellular energy. Research focuses on its ability to reverse age-related muscle decline (sarcopenia) and improve physical endurance by optimizing mitochondrial quality control.
The anti-inflammatory effects of Urolithin A extend across the blood-brain barrier. Current studies are investigating G. urolithinfaciens for its potential to reduce neuroinflammation in models of Alzheimer's and Parkinson's disease.
4. Immuno-Oncology
Recent patents and publications suggest that Gordonibacter abundance correlates with better responses to immune checkpoint inhibitors (e.g., anti-PD-1 therapy). Its ability to modulate the gut-immune axis makes it a compelling candidate for combination therapies in cancer treatment.
Why Partner With Creative Biolabs?
Navigating the preclinical landscape for Live Biotherapeutics requires more than just standard lab equipment—it requires deep microbiological expertise.
Anaerobic Excellence
We operate state-of-the-art anaerobic chambers and bioreactors, ensuring the viability of sensitive strains like G. urolithinfaciens from isolation to delivery.
Regulatory Alignment
Our study designs are built with IND (Investigational New Drug) requirements in mind, following guidelines for LBP safety and CMC (Chemistry, Manufacturing, and Controls).
Multi-Omics Integration
We don't just provide raw data. We integrate metagenomics, transcriptomics, and metabolomics to provide a holistic view of how the strain interacts with the host.
Proven Track Record
Our team has supported numerous successful preclinical filings for microbiome-based startups and global pharmaceutical firms alike.
Building the Future of Biotherapeutics
The potential of Gordonibacter urolithinfaciens to mitigate chronic disease through metabolic transformation is one of the most exciting developments in microbiome science. However, the path from "bench to bedside" is fraught with biological complexity and technical hurdles. At Creative Biolabs, we provide the specialized knowledge, cutting-edge technology, and rigorous scientific methodology needed to clear those hurdles. Whether you are a startup exploring a new LBP or an established firm looking to expand your microbiome portfolio, we are your strategic partner in preclinical excellence.
Is Gordonibacter urolithinfaciens safe for human consumption?
While G. urolithinfaciens is a natural inhabitant of the healthy human gut, as a therapeutic candidate, it must undergo rigorous safety assessments. Our services include GRAS (Generally Recognized as Safe) evaluation and tox-studies to confirm the absence of toxins and transferable antibiotic resistance.
How does this strain differ from Gordonibacter pamelaeae?
While both belong to the same genus, G. urolithinfaciens is specifically optimized for urolithin production. Our genomic comparative services can help you differentiate the metabolic efficiencies and niche specializations of different Gordonibacter species.
Can you help with the scale-up of this strain?
Yes. We provide process development services, moving from shake-flask cultures to 10L–50L bioreactors, optimizing cryopreservation and lyophilization protocols to maintain maximum viability (CFU/g).
What is the typical timeline for a gnotobiotic mouse study?
A standard colonization and efficacy study typically ranges from 8 to 14 weeks, depending on the complexity of the disease model and the endpoints required.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
